This review from a leader in the global aspects of pulmonary hypertension describes how what has been considered a rare disease, pulmonary hypertension, is actually quite common when one looks beyond the Western Countries and considers low-middle income countries.
This paper presents an argument for taking a global view of the problem of pulmonary vascular disease. Since pulmonary hypertension may be a marker for advanced cardiac and pulmonary diseases, it emphasizes the need to educate health care leaders to begin establishing regional centers of excellence so that a worldwide approach can be applied that will benefit all.
This is one of the more in-depth reviews of the global burden of pulmonary hypertension. They estimate a prevalence of 1% of the world population having pulmonary hypertension from any cause. They also estimate that the large majority of these patients (80%) live in developing countries, which emphasizes the challenge for both preventive and treatment strategies that will be affordable and accessible.
© Copyright 2023 Tenax Therapeutics. All Rights Reserved.
Site created by Top Shelf Design